| Li, Li |
NCT06697522: Study of Atropine Sulfate Eye Drops(0.01%) in Treating Near-work-induced Transient Myopia in Children |
|
|
| Completed | 3 | 148 | RoW | Atropine Sulfate, Investigational product, Placebo, Blank Solvent | Ocumension Therapeutics (Suzhou) Co., Ltd, Beijing Children's Hospital | Myopia | 10/23 | 03/24 | | |
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults |
|
|
| Completed | 3 | 286 | RoW | Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis | Cutia Therapeutics（Wuxi）Co.,Ltd | Analgesia | 08/23 | 10/23 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 240 | US | KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) | Krystal Biotech, Inc. | Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma | 07/27 | 07/27 | | |
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy |
|
|
| Recruiting | 1 | 40 | RoW | TQB2858 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cervical Cancer | 05/23 | 07/23 | | |
NCT06678581: SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects |
|
|
| Completed | 1 | 70 | RoW | SAP-001, SAP-001 tablet, Placebo, placebo tablet | Shanton Pharma Co., Ltd. | Gout, Hyperuricemia | 12/23 | 01/24 | | |
DEVIF-I, NCT06230822: Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 1 | 9 | RoW | VUM02 Injection, Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Idiopathic Pulmonary Fibrosis | 01/25 | 12/26 | | |
OASIS, NCT06063317: A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 33 | US | CF33-CD19 IT, CF33-CD19 IV, Blinatumomab, Blincyto | Imugene Limited | Solid Tumor, Adult | 06/27 | 05/29 | | |
| Su, Guanfang |
NCT05180526: Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV) |
|
|
| Active, not recruiting | 4 | 60 | RoW | QLETLI | Bio-Thera Solutions | Uveitis | 12/24 | 12/24 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
| Su |
NCT06683651: A Study in Chinese Patients With Acquired Blepharoptosis |
|
|
| Recruiting | 3 | 180 | RoW | STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800 | Santen Pharmaceutical Co., Ltd. | Blepharoptosis | 06/26 | 06/26 | | |
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation |
|
|
| Active, not recruiting | 1/2 | 315 | Europe, Canada, Japan, US, RoW | Sunvozertinib, DZD9008 | Dizal Pharmaceuticals | Non-Small Cell Lung Cancer | 07/24 | 07/25 | | |
| Xu, Xingxiang |
NCT05106335: A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC |
|
|
| Terminated | 3 | 1 | RoW | camrelizumab + famitinib, famitinib, docetaxel | Jiangsu HengRui Medicine Co., Ltd. | Advanced NSCLC | 05/22 | 05/22 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection |
|
|
| Recruiting | 3 | 80 | RoW | Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 03/26 | 03/26 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT05987371: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. |
|
|
| Recruiting | 2 | 72 | RoW | TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 01/24 | 03/24 | | |
NCT05815862: Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer |
|
|
| Recruiting | 2 | 40 | RoW | AL2846 capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Lung Cancer, Ovarian Cancer | 06/24 | 12/24 | | |
| Cai, Hanqing |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT05278338: Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis |
|
|
| Recruiting | 2 | 200 | RoW | JMT103, Denosumab, Placebo | Shanghai JMT-Bio Inc. | Postmenopausal Osteoporosis | 12/23 | 03/24 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
